Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.03
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of RAD.AX is 0.10 and suggests 233% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Data is available to registered users only
Buy
Sell